Microsoft Stock Is Getting Expensive. Should Investors Be Worried or Buy Anyway?
Microsoft continues to raise the bar despite difficult comps.
An expensive valuation will pressure Microsoft to keep delivering exceptional results.
Microsoft stock may be due for a pause, but it is still a long-term buy.
10 stocks we like better than Microsoft ›
Microsoft (NASDAQ: MSFT) has been a standout growth stock in 2025, adding more than $830 billion in market cap from the start of the year through the end of July. But some investors may be concerned that Microsoft is running up too far too fast, setting the stage for a pullback due to valuation concerns.
Here's why Microsoft's valuation is pretty much the only thing holding it back from being a screaming buy, and why the company can grow into its valuation over time.
Microsoft and the effectiveness of consistent compounding
Microsoft is a textbook example of the power of compounding solid growth over an extended period.
Over the last decade, cloud and artificial intelligence (AI) have been the two biggest drivers of Microsoft's sales and earnings growth. An honorable mention is the vertical integration of Microsoft's gaming business (under its More Personal Computing segment) through Xbox, content services, and the acquisition of Activision Blizzard.
Over the last decade, Microsoft's revenue more than tripled, and its net income is up more than sixfold. The company generated more net income in fiscal 2025 than revenue in fiscal 2017 -- illustrating the impact of high-margin growth on Microsoft's bottom line.
Fiscal Year
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue (billions)
$85.3
$90
$110.4
$125.8
$143
$168.1
$198.3
$211.9
$245.1
$281.7
Net income (billions)
$16.8
$21.2
$16.6
$39.2
$44.3
$69.9
$72.7
$72.4
$88.1
$101.8
Net profit margin
19.7%
23.6%
15%
31.2%
31%
41.6%
36.7%
34.2%
35.9%
36.1%
Data source: Microsoft.
Microsoft has been consistently growing revenue, but net income is growing even faster. In fiscal 2025, Microsoft raked in around $0.36 of every dollar in revenue into bottom-line profit. That's profit net of all expenses -- including taxes. That's an incredible achievement, especially considering how much Microsoft's expenses have gone up in recent years.
Microsoft is relatively expensive
Microsoft's rapid growth in the second half of the 2010s was driven by Azure and the widespread adoption of cloud computing. But everything has been clicking for Microsoft over the last three years. The company grew revenue by roughly 15% in fiscal 2023, 2024, and now 2025 -- surpassing $100 billion net income for a fiscal year for the first time in company history.
Microsoft's stock price responded to these impeccable results by compounding several-fold. And for a while, the valuation was arguably too cheap to ignore.
But now, Microsoft is being valued for what it has become, which is an ultra-high-margin, diversified business growing revenue in the mid-teens rather than the high single digits or low teens of years past. This valuation expansion has pushed Microsoft's price-to-earnings (P/E) ratio close to 40 -- whereas its 10-year median P/E is 33.1.
Growing into its valuation
Microsoft has never been a better company, but it has also become a much more expensive stock. Over time, Microsoft has justified its high valuation by consistently growing revenue and earnings. And now more than ever there's reason to believe that can continue.
Anything can happen in the stock market in the short term. But when it comes to long-term investing, buying ultra-high-quality companies at premium prices is usually worth it.
As an example, if Microsoft keeps growing earnings at 15% per year, earnings will double in five years.
If the stock price did nothing over that period, the P/E would be cut in half, down to around 20.
If the stock price gained another 50%, the P/E would fall to 30 -- a discount to Microsoft's historical average.
Justifying a premium price
Microsoft won't look expensive if it keeps up this pace of earnings growth. The power of compound returns is why the market is willing to pay a high price for Microsoft today.
As an individual investor, you have the luxury of choosing whether to agree with a prevailing sentiment. Right now, the sentiment is optimistic on Microsoft. So to buy the stock requires a long-term time horizon and the conviction that the optimism is grounded in logic rather than greed.
But if you believe that a lot of Microsoft's growth is due to a surge in AI adoption that will cool off as the technology becomes widespread, then it's perfectly all right to take a wait-and-see approach to the stock.
Do the experts think Microsoft is a buy right now?
The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Microsoft make the list?
When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!*
Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!*
The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 4, 2025
Daniel Foelber has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Microsoft Stock Is Getting Expensive. Should Investors Be Worried or Buy Anyway? was originally published by The Motley Fool

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
17 minutes ago
- Forbes
Microsoft Sued For Killing Windows 10—All Users Must Act Now
Microsoft knows 'many millions of users will not buy new devices or pay for extended support' when Windows 10 goes end of life in October, a new lawsuit alleges. 'These users,' it claims, 'will be at a heightened risk of a cyberattack or other data security incident, a reality of which Microsoft is well aware.' The lawsuit filed in California by Lawrence Klein, the owner of two Windows 10 laptops set to become obsolete in 8 weeks, 'seeks injunctive relief requiring Microsoft to continue providing support for Windows 10 without additional fees or conditions until the number of devices running the operating system falls below a reasonable threshold.' Around 45% of all Windows users are still on the soon to be obsolete version of the OS and must now act to ensure PCs are safe from attack. That number was dropping, albeit it has seen a reverse following Microsoft's decision to offer varying support extensions. That means 700 million users will be affected come October 14. Klein says Microsoft decided to kill the older OS when 'Windows 10 users represented more than half of the Windows operating system (OS) market share.' He also references the 240 million PCs that cannot upgrade, 'forcing' users to 'buy new devices capable of running Windows 11 or pay unanticipated sums for extended support.' Putting upgrade costs aside, the security risks are clear. Microsoft's 'long-term business strategy' Klein says, 'will have the effect of jeopardizing data security not only of Microsoft's customers but also of persons who may not use Microsoft's products at all.' Windows 10 users can now extend support by paying between $30 and $60 or by for free subject to certain parameters. That support extension is available to all Windows 10 users, whether or not their PCs meet the hardware requirements for Windows 11. Arguably, a better solution would be to extend Windows 10 support for free for PCs that can't upgrade, while mandating the upgrade for those that can. This lawsuit is the latest twist in a the windy road Windows 10 users have followed for the last year. Klein claims Microsoft's primary intent in killing Windows 10 is ' to force its customers to purchase new devices optimized to run Microsoft's suite of generative AI software such as Copilot, which comes bundled with Windows 11 by default.' This approach, Klein's lawsuit says, has the 'inevitable effect of decreasing trade in generative AI products of Microsoft's competitors, increasing the barriers to entry in the generative AI market, and dampening innovation and consumer choice.' Klein wants Windows 10 to be supported until less than 10% of the Windows user base is using that version of the OS. That means more than 600 million more PCs upgrading to Windows 11. That will take some considerable time. I have approached Microsoft for any response to the lawsuit.
Yahoo
an hour ago
- Yahoo
Why Nektar Therapeutics Stock Popped 6% on Friday
Key Points Investors were reacting to the biotech's second-quarter earnings report. Revenue was higher than analysts expected, although the net loss was deeper than the consensus. 10 stocks we like better than Nektar Therapeutics › Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, it was largely positive, and the share price increased by 6% today. This was well higher than the 0.8% gain posted by the S&P 500 index. Sweet results In its second quarter, Nektar booked total revenue of just under $11.2 million, which was less than half of the nearly $23.5 million in the same period of 2024. All of this derived from noncash royalty revenue connected to the sales of future royalties. This isn't unusual for a biotech without a commercialized product that depends on royalties and other payouts from partners. Nektar added that its cash and investments in marketable securities stood at just under $176 million at the end of the quarter (June 30). That, plus the roughly $107.5 million it should reap from a recent secondary share issue, should fund its operations into the first quarter of 2027. Meanwhile, the company's net loss for the second quarter was slightly over $39 million, or $2.78 per share. On average, analysts were projecting Nektar would book $9.7 million in revenue and a net loss of only $0.20 per share. I should note here that it can be challenging for even the most experienced professionals to estimate the results of biotechs that don't draw meaningful revenue from commercialized products. On a fast track All that said, there are several potential tailwinds for Nektar just now, and the company wasn't shy about itemizing them in its earnings release. Among the more promising is the U.S. Food and Drug Administration granting its Fast Track designation for rezpegaldesleukin, Nektar's investigational drug targeting severe-to-very-severe alopecia areata (a skin disorder). Do the experts think Nektar Therapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nektar Therapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nektar Therapeutics Stock Popped 6% on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Craig-Hallum Maintains Buy on Enphase (ENPH) Despite Clean Energy Headwinds
Enphase Energy, Inc. (NASDAQ:ENPH) is one of the best battery tech stocks to buy right now. Eric Stine, an analyst at Craig-Hallum, has kept a Buy rating on Enphase Energy, Inc. (NASDAQ:ENPH), without a price target. Stine showed continued support for the company despite ongoing challenges in the clean energy sector. While the solar industry has seen slower demand recently, some analysts still see room for growth in firms with strong technology and stable operations. A solar panel array stretched across a large open field, its glimmering panels reflecting the sun. Enphase Energy makes microinverters and energy management systems. These are used mainly in solar power setups, helping improve how energy is stored and used. The company has faced recent pressures, like weaker sales and cautious consumer spending, but it still holds a solid position in its field. Analysts believe that demand will return or that the company will adjust its costs and production to better fit market conditions. Though the stock has dropped since the end of 2022, some believe the lower price offers a chance for recovery. The analyst's decision to maintain a positive view could suggest belief in the company's ability to perform better in the future as the energy market changes. While we acknowledge the potential of ENPH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 10 Best Military Tech Stocks to Buy Now Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data